Who are I-131 Metaiodobenzylguanidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sr-89, Tc 99m filtered sulfur colloid, Technetium Tc99m Sestamibi, Fludeoxyglucose F 18 (FDG), Radium-223, Rubidium-82.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/i-131-metaiodobenzylguanidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

I-131 Metaiodobenzylguanidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

I-131 Metaiodobenzylguanidine (I-131 Metaiodobenzylguanidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; targeted radionuclide therapy. Area: Oncology.

phase 3 Radiopharmaceutical; targeted radionuclide therapy Norepinephrine transporter (NET) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

I-131 Metaiodobenzylguanidine (I-131 Metaiodobenzylguanidine) — M.D. Anderson Cancer Center. I-131 MIBG is a radioactive iodine-labeled compound that selectively accumulates in neuroendocrine tumors and delivers targeted radiation therapy to kill cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
I-131 Metaiodobenzylguanidine TARGET	I-131 Metaiodobenzylguanidine	M.D. Anderson Cancer Center	phase 3	Radiopharmaceutical; targeted radionuclide therapy	Norepinephrine transporter (NET)
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; targeted radionuclide therapy class)

M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). I-131 Metaiodobenzylguanidine — Competitive Intelligence Brief. https://druglandscape.com/ci/i-131-metaiodobenzylguanidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab